Foreign Companies in Drug/Pharmaceutical Sector

2069. SHRI S. AUSTIN: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that the foreign multinational companies operating in India in drug/pharmaceutical sector have hardly made any new investment in this sector since long;

(b) if so, the details of such companies which have more than 25 per cent foreign equity in drug sector; and

(c) the production of various drugs by each such company and import of those drugs during each of the last two years?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) No, Sir.

(b) Since 1990 industrial approvals involving investment of Rs. 104 crores have been given to companies which have more than 26% foreign equity.

(c) The production data of bulk drugs of individual companies or the company-wise data of imports are not monitored.

Purchase of imported Oxytetracycline

2070. SHRI RAJNI RANJAN SAHU:
DR. NARREDDY THULASI REDDY:
SHRIMATI SATYA BAHIN:
Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that large quantities of imported Oxytetracycline have been purchased by Pfizer and one or two other parties and if so, what are the details of the quantities produced and at what price;

(b) whether it is also a fact that large quantities of Tetracycline have been procured by M/s. Hoechst and M/s. Sandoz at price lower than
Government fixed price and if so, what are the details for the last three years;

(c) what steps have been taken to bring down the price of Doxycycline and the formulations, based on Tetracycline based on such procurement;

(d) whether it is a fact that Government is shielding such activity by dropping powers of recovery in such cases as were available under DPCO, 1979; and

(e) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) Company-wise imports of drugs/formulations are not monitored.

(c) The prices of bulk drugs are fixed/revised based on the study conducted by the Bureau of Industrial Costs and Prices, which is an expert body of the Government in this matter.

(d) No, Sir.

(e) Does not arise.

Increase in prices of non-scheduled formulations

2071. SHRI RAJNI RANJAN SAHU:
DR. NARREDDY THULASI REDDY:
SHRI ANANT RAM JAISWAL:
Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that drug companies have increased the prices of non-scheduled formulations having turnover of Rs. 3 crores per annum or more, very steeply;

(b) if so, what was the price of each pack, each such formulation having turnover of more than Rupees three crores in 1987, what is the price now and what is the percentage increase;

(c) whether it is a fact that bonus schemes have been introduced alongwith high rate of commissions and discounts at the level of chemists but prices for the consumers are not being reduced;

(d) the names of products in whose case bonus schemes and high commissions have been given during the last two years;

(e) what steps have been taken to put a stop to this wasteful practice;

(f) whether Government have proposed steps in the review of Drug Policy; and

(g) if so, the details thereof and if not, the reasons thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) No study of increase in prices of non-scheduled formulations vis-a-vis their turnover has been made. However, on the basis of a sample analysis, increases of more than 75% over the prices prevailing at the time of com-